Effects of microwave ablation or its combination with whole-body chemotherapy on serum vascular endothelial growth factor levels in patients with stage IIIB/IV NSCLC

Sun, Yan; Py, Song; Guo, Yuanxin; Pang, Min; Wn, He; Wh, Zhang; Lj, Sheng

doi:10.4238/2015.august.21.8

Cited by 6 publications

(2 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The local progression rate or relapse rate of patients in advanced-stage group was 20.5%, wherein, 81.3% of local progression or relapse occurred to the patients with a tumorous diameter of more than 3 cm. The study of Sun et al showed that the local relapse rate of IIIB-IV lung cancer treated by MWA therapy was 26.8% (28). These results indicated that the patients in advanced-stage group were vulnerable to local progression or relapse, and the greater the tumorous diameter, the more possible local progression or relapse would happen.…”

Section: Discussionmentioning

confidence: 97%

Clinical analysis on 113 patients with lung cancer treated by percutaneous CT-guided microwave ablation

et al. 2017

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 97%

Clinical analysis on 113 patients with lung cancer treated by percutaneous CT-guided microwave ablation

et al. 2017

View full text Add to dashboard Cite

show abstract

“…A retrospective study on HCC patients showed no significant differences in VEGF and HGF receptors between patients treated with MWA and those treated with resection; on the other hand, in NSCLC, VEGF levels were found to be significantly increase after MWA [ 112 , 113 ].…”

Section: Invasive Percutaneous Lrtsmentioning

confidence: 99%

Interventional Radiology Image-Guided Locoregional Therapies (LRTs) and Immunotherapy for the Treatment of HCC

Biondetti

Saggiante

Ierardi

et al. 2021

Cancers

View full text Add to dashboard Cite

Image-guided locoregional therapies (LRTs) are a crucial asset in the treatment of hepatocellular carcinoma (HCC), which has proven to be characterized by an impaired antitumor immune status. LRTs not only directly destroy tumor cells but also have an immunomodulating role, altering the tumor microenvironment with potential systemic effects. Nevertheless, the immune activation against HCC induced by LRTs is not strong enough on its own to generate a systemic significant antitumor response, and it is incapable of preventing tumor recurrence. Currently, there is great interest in the possibility of combining LRTs with immunotherapy for HCC, as this combination may result in a mutually beneficial and synergistic relationship. On the one hand, immunotherapy could amplify and prolong the antitumoral immune response of LRTs, reducing recurrence cases and improving outcome. On the other hand, LTRs counteract the typical immunosuppressive HCC microenvironment and status and could therefore enhance the efficacy of immunotherapy. Here, after reviewing the current therapeutic options for HCC, we focus on LRTs, describing for each of them the technique and data on its effect on the immune system. Then, we describe the current status of immunotherapy and finally report the recently published and ongoing clinical studies testing this combination.

show abstract

Survival benefit of thermal ablation combined with chemotherapy for the treatment of stage IV nonsmall cell lung cancer: a propensity-matched analysis

Yang

Mei

2022

International Journal of Hyperthermia

View full text Add to dashboard Cite

Effects of microwave ablation or its combination with whole-body chemotherapy on serum vascular endothelial growth factor levels in patients with stage IIIB/IV NSCLC

Cited by 6 publications

References 18 publications

Clinical analysis on 113 patients with lung cancer treated by percutaneous CT-guided microwave ablation

Clinical analysis on 113 patients with lung cancer treated by percutaneous CT-guided microwave ablation

Interventional Radiology Image-Guided Locoregional Therapies (LRTs) and Immunotherapy for the Treatment of HCC

Survival benefit of thermal ablation combined with chemotherapy for the treatment of stage IV nonsmall cell lung cancer: a propensity-matched analysis

Contact Info

Product

Resources

About